Copyright
©The Author(s) 2024.
World J Diabetes. Sep 15, 2024; 15(9): 1962-1978
Published online Sep 15, 2024. doi: 10.4239/wjd.v15.i9.1962
Published online Sep 15, 2024. doi: 10.4239/wjd.v15.i9.1962
Figure 6 In vivo experiments demonstrated that macrophage clearance can improve intestinal function and epithelium integrity.
We depleted macrophages using clodronate liposomes in mice to elucidate the role of macrophages in intestinal injury. A-D: Hematoxylin and eosin staining revealed less severe injury in mice treated with clodronate liposomes; E-L: Immunofluorescence analysis demonstrated a significant induction in ZO-1 and reduction in CD86 levels 24 hours after clodronate liposome treatment; M and N: Immunofluorescence analysis revealed a significant increase in the protein expression of CD86 and ZO-1 in MMP23 knockout mice. Scale bar = 50 μm. aP < 0.05, bP < 0.01, cP < 0.001, dP < 0.0001. DB: Diabetes group.
- Citation: Lu M, Guo XW, Zhang FF, Wu DH, Xie D, Luo FQ. Dexmedetomidine ameliorates diabetic intestinal injury by promoting the polarization of M2 macrophages through the MMP23B pathway. World J Diabetes 2024; 15(9): 1962-1978
- URL: https://www.wjgnet.com/1948-9358/full/v15/i9/1962.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i9.1962